BARDA and DoD work with SiO2 Materials Science to increase domestic manufacturing of vials
BARDA joined forces with the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) and SiO2 Materials Science to accelerate the production and scale-up of SiO2’s patented packaging platform for storing vaccines and therapeutics for use in the current pandemic, if needed, or future public health emergencies.
Increasing the capacity to manufacture vials in the United States can reduce U.S. dependence on foreign supply chains, help meet industry demands, and ensure that any surge in the demand for vials due to the COVID-19 vaccine and therapeutic developments can be accommodated without delays. With the help from the federal government, SiO2’s annual production capability will reach 120 million vials by the end of 2020 and could exceed one billion vials by April 2021, enabling maximum availability of the future FDA-approved COVID-19 vaccine.
SiO2 Materials Science (SiO2) produces high-performance, durable, glass-equivalent vaccine vials to store, transport, and protect vaccines.
The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.
SiO2 Materials Science is a privately owned U.S. advanced materials science corporation which has invented a hybrid material which combines the benefits of both glass and plastic. The hybrid material is used in the pharmaceutical, genomics & diagnostics, and consumer healthcare industries. The company is located in Auburn, Alabama. The company has deep partnerships with leading professors at the foremost research universities such as University of California, University of Chicago, MIT, and CalTech.